---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004578"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:26:10.915868+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Treace Medical preliminary Q4 rev ~$68.6M, FY2024 ~$209.2M, up 12% YoY

## Summary
- Preliminary Q4 revenue $68.4M-$68.8M, ~10% increase at midpoint vs Q4 2023.
- Full-year 2024 revenue $209.0M-$209.4M, ~12% growth at midpoint, in line with $204M-$211M guidance.
- Added ~280 active surgeons in 2024; total ~3,135 active surgeons (+10% YoY), ~31% of US bunion surgeon market.
- 2025 financial guidance to be provided during Q4 2024 earnings call on Feb 27, 2025.
- Management to present at J.P. Morgan Healthcare Conference on Jan 14, 2025.

## SEC filing metadata
- accession: 0000950170-25-004578
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017025004578/0000950170-25-004578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017025004578/tmci-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004578
- JSON: https://secwatch.observer/filing/0000950170-25-004578.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.